Overexpression of the HER-2/Neu tyrosine kinase receptor causes dysregulation of Raf/MEK/MAPK oncogenic signalling, which leads to chemoendocrine resistance, the development of distant metastases, and ultimately a poor prognosis in breast cancer patients (Leontovich et al., 2012). This evidence concerns the gene RAF1 and breast carcinoma.